Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
Journal: 2013/August - Gynecological Endocrinology
ISSN: 1473-0766
Abstract:
OBJECTIVE
To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of polycystic ovary syndrome (PCOS) patients.
METHODS
Controlled clinical study.
METHODS
PCOS patients in a clinical research environment.
METHODS
50 overweight PCOS patients were enrolled after informed consent.
METHODS
All patients underwent hormonal evaluations and an oral glucose tolerance test (OGTT) before and after 12 weeks of therapy (Group A (n¼10): MYO 2 g plus folic acid 200 mg every day; Group B (n¼10): folic acid 200 mg every day). Ultrasound examinations and Ferriman-Gallwey score were also performed.
METHODS
Plasma LH, FSH, PRL, E2, 17OHP, A, T, glucose, insulin, C peptide concentrations, BMI, HOMA index and glucose-to-insulin ratio.
RESULTS
After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment. Menstrual cyclicity was restored in all amenorrheic and oligomenorrheic subjects. No changes occurred in the patients treated with folic acid.
CONCLUSIONS
MYO administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion.
Relations:
Citations
(18)
Diseases
(2)
Drugs
(24)
Chemicals
(6)
Organisms
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.